- Sector News
- Opinion and Analysis
- Virtus Report
Subscribe to stay informed!
Discover hidden stock market gems and stay up to date with our weekly email newsletter and individual stock ideas
Citigroup has started covering Arrowhead Pharmaceuticals (ARWR) and has given it a neutral recommendation, according to Fintel. This initiation of coverage took place on September 19, 2023. The average price target for Arrowhead Pharmaceuticals as of August 31, 2023, is $59.71, with forecasts ranging from $27.27 to $94.50. This suggests a potential upside of 112.26% from the latest reported closing price of $28.13. Arrowhead Pharmaceuticals is projected to have annual revenue of $309 million, representing an increase of 20.76%. The projected annual non-GAAP EPS is -1.78. There are currently 591 funds or institutions reporting positions in Arrowhead Pharmaceuticals, which is an increase of 15 owners or 2.60% in the last quarter. The average portfolio weight of all funds dedicated to ARWR is 0.21%, indicating an increase of 18.22%. Institutions’ total shares owned decreased by 3.19% in the last three months to 79,636K shares. The put/call ratio of ARWR is 0.32, suggesting a bullish outlook. In terms of other shareholders, iShares Core S&P Mid-Cap ETF (IJH) holds 3,243K shares, representing 3.03% ownership of the company. This is a decrease of 3.04% compared to its previous filing. Vanguard Total Stock Market Index Fund Investor Shares (VTSMX) holds 3,227K shares, representing 3.01% ownership, indicating an increase of 0.33%. Jpmorgan Chase holds 2,881K shares, representing 2.69% ownership, which is a decrease of 1.01%. Vanguard Small-Cap Index Fund Investor Shares (NAESX) holds 2,622K shares, representing 2.45% ownership, with a decrease of 2.73%. iShares Russell 2000 ETF (IWM) holds 2,322K shares, representing 2.17% ownership, indicating an increase of 3.84%. Arrowhead Pharmaceuticals develops RNA-based medicines that target genes causing intractable diseases. Their therapies utilize RNA interference (RNAi) to silence specific genes and affect protein production. RNAi is a natural mechanism present in living cells that inhibits gene expression. This pathway of gene silencing is the foundation of Arrowhead’s RNAi-based therapeutics. Fintel is an investing research platform that provides comprehensive data to individual investors, traders, financial advisors, and small hedge funds. Their data includes fundamentals, analyst reports, ownership data, fund sentiment, insider trading, options flow, unusual options trades, and more. Their stock picks are powered by advanced, backtested quantitative models for improved profits. For further information, you can visit Fintel’s website. Please note that the views and opinions expressed in this article are those of the author and do not necessarily reflect those of Nasdaq, Inc.
A writer and finance enthusiast who loves diving into the exciting world of stocks, commodities, forex, and crypto. I'm all about making the financial markets less intimidating and more accessible, so I write engaging content that simplifies complex concepts and shares practical investment strategies. Whether you're a seasoned investor or just getting started, I've got your back! But hey, life isn't all about work, right? On weekends, you'll find me hanging out and having a blast with my awesome friends and family. We love bonding over shared interests, trying out new adventures, and simply enjoying each other's company. Striking that balance between work and play is super important to me, because what's the point of success if you can't share it with the people you love? So, if you're up for some financial market insights and a good dose of weekend fun, stick around! Together, we'll navigate the money world and make the most of our time off. Let's learn, grow, and create memories along the way!